PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

[1]  H. Dauerman,et al.  A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of th , 2009, Journal of Thrombosis and Thrombolysis.

[2]  A. Harris,et al.  Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[3]  A. Lau,et al.  4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. , 2008, Journal of medicinal chemistry.

[4]  E. Siles,et al.  PARP‐1 modulates deferoxamine‐induced HIF‐1α accumulation through the regulation of nitric oxide and oxidative stress , 2008, Journal of cellular biochemistry.

[5]  Alessandro De Luca,et al.  Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. , 2008, Gynecologic oncology.

[6]  C. Szabó,et al.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. , 2008, The American journal of pathology.

[7]  A. Papapetropoulos,et al.  Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. , 2008, International journal of molecular medicine.

[8]  A. Lau,et al.  Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin , 2008, Clinical Cancer Research.

[9]  E. Mazzon,et al.  Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. , 2008, European journal of cancer.

[10]  J. Carmichael,et al.  AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study , 2008 .

[11]  Elizabeth Iorns,et al.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor , 2008, The EMBO journal.

[12]  S. Batkai,et al.  Poly(ADP‐ribose)polymerase inhibition decreases angiogenesis. , 2008 .

[13]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[14]  A. Ashworth,et al.  DNA repair deficiency as a therapeutic target in cancer. , 2008, Current opinion in genetics & development.

[15]  L. Milas,et al.  INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin , 2008, Investigational New Drugs.

[16]  E. González-Rey,et al.  Therapeutic Effect of a Poly(ADP-Ribose) Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response , 2007, PloS one.

[17]  R. Tuma.  Combining carefully selected drug, patient genetics may lead to total tumor death. , 2007, Journal of the National Cancer Institute.

[18]  D. Roukos,et al.  Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome , 2007, Nature Clinical Practice Oncology.

[19]  C. Szabó,et al.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. , 2007, Cardiovascular drug reviews.

[20]  Zhao-Qi Wang,et al.  Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice , 2007, Oncogene.

[21]  David H. Johnson,et al.  Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models , 2007, Clinical Cancer Research.

[22]  R. I. Viji,et al.  Endothelial cell response to lactate: Implication of PAR modification of VEGF , 2007, Journal of cellular physiology.

[23]  Eric F. Johnson,et al.  ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models , 2007, Clinical Cancer Research.

[24]  C. Leonetti,et al.  Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. , 2007, European journal of cancer.

[25]  J. Ménissier-de murcia,et al.  Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition , 2007, BMC Molecular Biology.

[26]  J. Low,et al.  Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology , 2007, Clinical Cancer Research.

[27]  A. Ashworth,et al.  The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability , 2006, Oncogene.

[28]  Peter S. Linsley,et al.  Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions , 2006, Molecular and Cellular Biology.

[29]  C. Eipel,et al.  Protective effects of PARP inhibition on liver microcirculation and function after haemorrhagic shock and resuscitation in male rats , 2006, Intensive Care Medicine.

[30]  G. Kingsley,et al.  Tumor necrosis factor inhibitors for rheumatoid arthritis. , 2006, The New England journal of medicine.

[31]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[32]  C. Deng,et al.  PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? , 2006, International journal of medical sciences.

[33]  J. Papp,et al.  Activation of the Poly(ADP-Ribose) Polymerase Pathway in Human Heart Failure , 2006, Molecular medicine.

[34]  V. Schreiber,et al.  Poly(ADP-ribose): novel functions for an old molecule , 2006, Nature Reviews Molecular Cell Biology.

[35]  R. Plummer,et al.  First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Deng,et al.  The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors , 2006, International journal of biological sciences.

[37]  M. Yorek,et al.  Poly(ADP-Ribose) Polymerase Inhibition Alleviates Experimental Diabetic Sensory Neuropathy , 2006, Diabetes.

[38]  M. Piris,et al.  Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. , 2006, Cancer research.

[39]  T. Helleday,et al.  Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair , 2006, Nucleic acids research.

[40]  T. K. Hunt,et al.  IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase. , 2006, Biochemical and biophysical research communications.

[41]  D. Weinstock,et al.  A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair. , 2006, Blood.

[42]  M. Yorek,et al.  Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. , 2005, Diabetes.

[43]  O. Sansom,et al.  Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. , 2005, Cancer research.

[44]  T. Stankovic,et al.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.

[45]  A. Ashworth,et al.  Targeting the DNA repair defect of BRCA tumours. , 2005, Current opinion in pharmacology.

[46]  T. Helleday,et al.  Poly(ADP-ribose) Polymerase (PARP-1) in Homologous Recombination and as a Target for Cancer Therapy , 2005, Cell cycle.

[47]  Z. Ungvari,et al.  Role of oxidative and nitrosative stress, longevity genes and poly(ADP-ribose) polymerase in cardiovascular dysfunction associated with aging. , 2005, Current vascular pharmacology.

[48]  M. Malanga,et al.  The role of poly(ADP-ribose) in the DNA damage signaling network. , 2005, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[49]  S. Kern,et al.  Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition , 2005, Cancer biology & therapy.

[50]  Csaba Szabó,et al.  Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors , 2005, Nature Reviews Drug Discovery.

[51]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[52]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[53]  C. Szabó,et al.  Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma. , 2005, Current drug targets. CNS and neurological disorders.

[54]  H. Nakajima,et al.  A Newly Synthesized Poly(ADP-Ribose) Polymerase Inhibitor, DR2313 [2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: Pharmacological Profiles, Neuroprotective Effects, and Therapeutic Time Window in Cerebral Ischemia in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[55]  T. Helleday,et al.  Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. , 2004, Biochemical Society transactions.

[56]  C. Szabó,et al.  Poly(ADP-Ribose) Polymerase Is Involved in the Development of Diabetic Retinopathy via Regulation of Nuclear Factor-κB , 2004 .

[57]  C. Szabó,et al.  The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with Immunomodulation , 2004, Journal of Pharmacology and Experimental Therapeutics.

[58]  A. Iwashita,et al.  A Novel and Potent Poly(ADP-Ribose) Polymerase-1 Inhibitor, FR247304 (5-Chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), Attenuates Neuronal Damage in in Vitro and in Vivo Models of Cerebral Ischemia , 2004, Journal of Pharmacology and Experimental Therapeutics.

[59]  G. de Murcia,et al.  The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[60]  M. Valenzuela,et al.  Crosstalk between PARP-1 and NF-κB modulates the promotion of skin neoplasia , 2004, Oncogene.

[61]  I. Shymanskyy,et al.  Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy. , 2004, Journal of diabetes and its complications.

[62]  H. Ha.  Defective transcription factor activation for proinflammatory gene expression in poly(ADP-ribose) polymerase 1-deficient glia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Fei Li,et al.  Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. , 2004, Diabetes.

[64]  N. Curtin,et al.  Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells , 2004, Clinical Cancer Research.

[65]  C. Szabó,et al.  Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. , 2004, Oncology reports.

[66]  Robert Almassy,et al.  Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. , 2004, Journal of the National Cancer Institute.

[67]  R. Kowluru,et al.  Diabetes-induced mitochondrial dysfunction in the retina. , 2003, Investigative ophthalmology & visual science.

[68]  M. Fattahi,et al.  Histochemical assessment of nitric oxide synthase activity in aortic endothelial cells of streptozotocin-induced diabetic rats. , 2003, Pathophysiology : the official journal of the International Society for Pathophysiology.

[69]  M. Hottiger,et al.  Transcriptional Coactivation of Nuclear Factor-κB-dependent Gene Expression by p300 Is Regulated by Poly(ADP)-ribose Polymerase-1* , 2003, Journal of Biological Chemistry.

[70]  Antonio Ceriello,et al.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. , 2003, Diabetes.

[71]  Antonio Ceriello,et al.  Oxidative Stress in Diabetes , 2003, Clinical chemistry and laboratory medicine.

[72]  D. Zochodne,et al.  Sensory neurons with activated caspase-3 survive long-term experimental diabetes. , 2003, Diabetes.

[73]  T. Helleday,et al.  Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. , 2003, Nucleic acids research.

[74]  C. Szabó,et al.  Diabetes‐induced overexpression of endothelin‐1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP‐ribose) polymerase activation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[75]  A. Kang,et al.  Immunopathogenesis of Collagen Arthritis , 2003, Springer Seminars in Immunopathology.

[76]  C. Szabó,et al.  Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. , 2003, Diabetes.

[77]  G. Costantino,et al.  Novel Isoquinolinone-Derived Inhibitors of Poly(ADP-ribose) Polymerase-1: Pharmacological Characterization and Neuroprotective Effects in an in Vitro Model of Cerebral Ischemia , 2003, Journal of Pharmacology and Experimental Therapeutics.

[78]  G. Poirier,et al.  PARP-1, a determinant of cell survival in response to DNA damage. , 2003, Experimental hematology.

[79]  S. Skaper.  Poly(ADP‐Ribose) Polymerase‐1 in Acute Neuronal Death and Inflammation , 2003 .

[80]  É. Szabó,et al.  Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. , 2003, Toxicology letters.

[81]  B. Ruggeri,et al.  Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. , 2003, Molecular cancer therapeutics.

[82]  K. Kröncke,et al.  Necrosis Is the Predominant Type of Islet Cell Death During Development of Insulin-Dependent Diabetes Mellitus in BB Rats , 2003, Laboratory Investigation.

[83]  David J. Chen,et al.  Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice , 2003, Genes, chromosomes & cancer.

[84]  J. Groves,et al.  Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction , 2003, Circulation.

[85]  M. O’connor,et al.  Poly(ADP-Ribose) Polymerase-1 Regulates Activation of Activator Protein-1 in Murine Fibroblasts1 , 2003, The Journal of Immunology.

[86]  C. Szabó,et al.  Poly(ADP-ribose) polymerase inhibitors. , 2003, Current medicinal chemistry.

[87]  L. Formigli,et al.  Beneficial Effects of Poly (ADP-ribose) Polymerase Inhibition Against the Reperfusion Injury in Heart Transplantation , 2003, Free radical research.

[88]  S. Ye,et al.  Specific interference with gene expression and gene function mediated by long dsRNA in neural cells , 2002, Journal of Neuroscience Methods.

[89]  W. Quist,et al.  Poly(ADP-Ribose) Polymerase Is Activated in Subjects at Risk of Developing Type 2 Diabetes and Is Associated With Impaired Vascular Reactivity , 2002, Circulation.

[90]  A. Chiarugi.  Inhibitors of poly(ADP‐ribose) polymerase‐1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats , 2002, British journal of pharmacology.

[91]  Yangzheng Feng,et al.  Drug-induced hypothermia begun 5 minutes after injury with a poly(adenosine 5′-diphosphate-ribose) polymerase inhibitor reduces hypoxic brain injury in rat pups* , 2002, Critical care medicine.

[92]  N. Curtin,et al.  Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. , 2002, Journal of medicinal chemistry.

[93]  C. Szabó,et al.  Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. , 2002, Journal of the American College of Cardiology.

[94]  P. Dollé,et al.  Poly(ADP-ribose) Polymerase-2 (PARP-2) Is Required for Efficient Base Excision DNA Repair in Association with PARP-1 and XRCC1* , 2002, The Journal of Biological Chemistry.

[95]  L. Giovannelli,et al.  Comet Assay as a Novel Approach for Studying DNA Damage in Focal Cerebral Ischemia: Differential Effects of NMDA Receptor Antagonists and Poly(ADP-Ribose) Polymerase Inhibitors , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[96]  J. Parrillo,et al.  Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis* , 2002, Critical care medicine.

[97]  M. Feldmann,et al.  Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.

[98]  K. Channon,et al.  Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase , 2002, Circulation.

[99]  S. Mori,et al.  Poly(ADP-Ribose) Polymerase Impairs Early and Long-Term Experimental Stroke Recovery , 2002, Stroke.

[100]  C. Szabó,et al.  Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. , 2002, The Journal of pharmacology and experimental therapeutics.

[101]  É. Szabó,et al.  The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. , 2002, Diabetes.

[102]  M. Covic,et al.  The Enzymatic and DNA Binding Activity of PARP-1 Are Not Required for NF-κB Coactivator Function* , 2001, The Journal of Biological Chemistry.

[103]  C. Szabó,et al.  Rapid Reversal of the Diabetic Endothelial Dysfunction by Pharmacological Inhibition of Poly(ADP-Ribose) Polymerase , 2001, Circulation research.

[104]  A. Ashworth,et al.  Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences , 2001, The EMBO journal.

[105]  É. Szabó,et al.  Suppression of poly (ADP‐ribose) polymerase activation by 3‐aminobenzamide in a rat model of myocardial infarction: long‐term morphological and functional consequences , 2001, British journal of pharmacology.

[106]  J. Kline,et al.  Activation of poly(ADP-ribose) polymerase in severe hemorrhagic shock and resuscitation. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[107]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[108]  J. Callés-Escandon,et al.  Diabetes and endothelial dysfunction: a clinical perspective. , 2001, Endocrine reviews.

[109]  S. Takasawa,et al.  Activation of Reg gene, a gene for insulin-producing beta -cell regeneration: poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly(ADP-ribosyl)ation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[110]  P. Wang,et al.  Critical role of oxygen radicals in the initiation of hepatic depression after trauma hemorrhage. , 2000, The Journal of trauma.

[111]  D. Ly,et al.  Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[112]  É. Szabó,et al.  Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[113]  V. Rotter,et al.  A Fast Signal–Induced Activation of Poly(Adp-Ribose) Polymerase , 2000, The Journal of cell biology.

[114]  S. Hussain,et al.  Role of poly-(ADP-ribose) synthetase in lipopolysaccharide-induced vascular failure and acute lung injury in pigs. , 2000, Journal of critical care.

[115]  B. Koller,et al.  Brca1 controls homology-directed DNA repair. , 1999, Molecular cell.

[116]  M. Clemens,et al.  Inhibition of poly(ADP-ribose) synthetase improves vascular contractile responses following trauma-hemorrhage and resuscitation. , 1999, Shock.

[117]  G. Poirier,et al.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.

[118]  R. Andriantsitohaina,et al.  Resistance to endotoxic shock as a consequence of defective NF‐κB activation in poly (ADP‐ribose) polymerase‐1 deficient mice , 1999, The EMBO journal.

[119]  J. Greenberg,et al.  The effect of reperfusion on neuroprotection using an inhibitor of poly(ADP-ribose) polymerase. , 1999, Neuroreport.

[120]  S. Snyder,et al.  Poly (ADP-ribose) polymerase, nitric oxide and cell death. , 1999, Trends in pharmacological sciences.

[121]  S. Snyder,et al.  Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[122]  Hiroshi Suzuki,et al.  Function of poly(ADP-ribose) polymerase in response to DNA damage: Gene-disruption study in mice , 1999, Molecular and Cellular Biochemistry.

[123]  D. Anthony,et al.  Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis. , 1999, Clinical and experimental rheumatology.

[124]  H. Kolb,et al.  Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin , 1999, Nature Medicine.

[125]  Nadia Smail,et al.  Hypoxemia in the absence of blood loss upregulates iNOS expression and activity in macrophages. , 1999, American journal of physiology. Cell physiology.

[126]  K. Nozaki,et al.  Enhanced Poly(ADP-ribosyl)ation after Focal Ischemia in Rat Brain , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[127]  B. Zingarelli,et al.  Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. , 1998, Circulation research.

[128]  V. Dawson,et al.  Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. , 1998, Trends in pharmacological sciences.

[129]  Matthias Endres,et al.  Role of peroxynitrite and neuronal nitric oxide synthase in the activation of poly(ADP-ribose) synthetase in a murine model of cerebral ischemia-reperfusion , 1998, Neuroscience Letters.

[130]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[131]  C. Le Page,et al.  Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF kappa B activation. , 1998, Biochemical and biophysical research communications.

[132]  B. Ponder,et al.  Involvement of Brca2 in DNA repair. , 1998, Molecular cell.

[133]  M. Moskowitz,et al.  Ischemic Brain Injury is Mediated by the Activation of Poly(ADP-Ribose)Polymerase , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[134]  J Zhang,et al.  Neuroprotective Effects of Inhibiting Poly(ADP-Ribose) Synthetase on Focal Cerebral Ischemia in Rats , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[135]  S. Snyder,et al.  Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia , 1997, Nature Medicine.

[136]  E. Wagner,et al.  PARP is important for genomic stability but dispensable in apoptosis. , 1997, Genes & development.

[137]  S. Cuzzocrea,et al.  Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. , 1997, The Journal of clinical investigation.

[138]  P. Chambon,et al.  Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[139]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[140]  C. Iadecola.  Bright and dark sides of nitric oxide in ischemic brain injury , 1997, Trends in Neurosciences.

[141]  R. Wenzel,et al.  Current understanding of sepsis. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[142]  M. Feldmann,et al.  Interleukin-10 inhibition of the progression of established collagen-induced arthritis. , 1996, Arthritis and rheumatism.

[143]  H. Kolb,et al.  Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells , 1995, The Journal of Biological Chemistry.

[144]  D. Easton,et al.  Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. , 1995, Oncogene.

[145]  A. Sommer,et al.  Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. , 1995, Biological chemistry Hoppe-Seyler.

[146]  M. Moskowitz,et al.  Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. , 1994, Science.

[147]  D. Easton,et al.  Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome , 1992, Nature Genetics.

[148]  K. Ueda,et al.  Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. , 1992, The Journal of biological chemistry.

[149]  K. Nonaka,et al.  Nicotinamide and 3‐aminobenzamide inhibit recombinant human interferon‐γ‐induced HLA‐DR antigen expression, but not HLA‐A, B, C antigen expression, on cultured human thyroid cells , 1992, Clinical endocrinology.

[150]  F. Moroni,et al.  Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[151]  K. Milam,et al.  Inhibitors of poly(adenosine diphosphate-ribose) synthesis: effect on other metabolic processes. , 1984, Science.

[152]  M. R. Purnell,et al.  Novel inhibitors of poly(ADP-ribose) synthetase. , 1980, The Biochemical journal.

[153]  P. Chambon,et al.  Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. , 1963, Biochemical and biophysical research communications.

[154]  L. Liaudet,et al.  Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.

[155]  H. Kröger,et al.  Inhibition of the induction of collagenase by interleukin-1 β in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide , 2004, Rheumatology International.

[156]  M. Suedkamp,et al.  Nitrotyrosine and 8-isoprostane formation indicate free radical-mediated injury in hearts of patients subjected to cardioplegia. , 2003, The Journal of thoracic and cardiovascular surgery.

[157]  K. Murthy,et al.  Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation , 2001, Nature Medicine.

[158]  M. Perretti,et al.  Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase , 2001, Inflammation Research.

[159]  Z. Yang,et al.  Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. , 2000, Shock.

[160]  V. Schreiber,et al.  Involvement of poly(ADP-ribose) polymerase in base excision repair. , 1999, Biochimie.

[161]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[162]  N. Berger,et al.  Poly(ADP-ribose) polymerase mediates the suicide response to massive DNA damage: studies in normal and DNA-repair defective cells. , 1983, Princess Takamatsu symposia.

[163]  Serveur Académique Lausannois SERVAL serval.unil.ch , 2022 .